Tag: PRRT

UI neuroendocrine tumor program earns high European distinction

University of Iowa Holden Comprehensive Cancer Center is the first U.S. cancer center to be designated a Neuroendocrine Tumor Center of Excellence by the European Neuroendocrine Tumor Society (ENETS). In making the award to the Iowa team in early March, ENETS…

Continue Reading UI neuroendocrine tumor program earns high European distinction

PRRT is finally approved in the U.S.

After years of randomized trials and nearly two decades of European data detailing peptide receptor radionuclide therapy, Advanced Accelerator Applications (AAA), a Novartis company, is pleased to announced that the FDA has approved the use of this therapy for patients…

Continue Reading PRRT is finally approved in the U.S.

Dr. Thor & Dr. Tuba present The Future of PRRT & The Team Approach

On January 14, 2018, Dr. Thor Halfdanarson and Dr. A. Tuba Kendi from Mayo Clinic Rochester presented to Northwoods NETS. Dr. Tuba, a radiologist from Mayo, has been fronting the Gallium-68 PET/MRI scan center that has been helping detect and…

Continue Reading Dr. Thor & Dr. Tuba present The Future of PRRT & The Team Approach

Part Twelve: Where PRRT & Me part ways

In August, I went to see my specialist in Iowa City and was presented with terrible news. The lesions in my liver went to 5% tumor burden in January 2017 to 30% tumor burden in August 2017. PRRT was completely…

Continue Reading Part Twelve: Where PRRT & Me part ways

FDA: Lutathera Action Date Set for Late January 2018

Advanced Accelerator Applications S.A. (AAA) has announced that the Food and Drug Administration (FDA), in the United States, has accepted and considered complete the resubmission of the New Drug Application (NDA) for its investigational drug lutetium Lu 177 dotatate (Lutathera).  Lutathera…

Continue Reading FDA: Lutathera Action Date Set for Late January 2018

Part Eleven: In front of the eight ball

So, it’s been a ridiculously long time since I posted and for that, I am sorry. I meant to update in May as a one-year anniversary of my first round of treatment and I was still slogging through some side…

Continue Reading Part Eleven: In front of the eight ball

Expanded Access to PRRT in the United States

We have exciting news in regards to Peptide Receptor Radionuclide Therapy (PRRT) therapy in the United States. Advanced Accelerator Applications is currently pursuing marketing approval for 177Lu-DOTA0-Tyr3-Octreotate (Lutathera). Considering that Phase III NETTER-1 clinical trial recruitment has been completed, this expanded…

Continue Reading Expanded Access to PRRT in the United States

Part Ten: Round Three was a doozy

I left for Europe a week earlier this time to visit Munich with my sister and Oktoberfest. It was actually her first ever trip to Europe and even though I did round two by myself, it was nice to have…

Continue Reading Part Ten: Round Three was a doozy

Part Eight: Round Two – Dancing with Lu-177 | PRRT & Me

Woah! I wrote a few weeks ago and I thought I’d have plenty of time to blog before I went to Basel for round two and the time slipped away. I am already done with round two. My treatment date…

Continue Reading Part Eight: Round Two – Dancing with Lu-177 | PRRT & Me

Part Seven: Ten Weeks before Round Two | PRRT & Me

We stayed in Switzerland for a few days after my first round and that was fine. I didn’t really have any side effects, but, I was tired. The only real thing I noticed is that I was having some acid…

Continue Reading Part Seven: Ten Weeks before Round Two | PRRT & Me